カリフォルニア州における神経芽腫の臨床試験
カリフォルニア州内の拠点で、神経芽腫に関する14件の研究が参加者を募集しています。
カリフォルニア州内の都市
公式研究テキスト（英語）
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Kaiser Permanente Downey Medical Center, Downey
- City of Hope Comprehensive Cancer Center, Duarte
- Loma Linda University Medical Center, Loma Linda
- 他13件
被験者募集中第3相
30歳以下 · 全性別 · 2026/10/02更新 · NCT06172296MCT for the Harvard/UCSF ROBIN Center
- University of California, San Francisco, San Francisco
被験者募集中
全年齢 · 全性別 · 2026/10/01更新 · NCT06000787Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital Los Angeles ( Site 1006), Los Angeles
被験者募集中第1/2相
6 Months – 25 Years · 全性別 · 2026/09/17更新 · NCT06395103Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- UCSF Benioff Children's Hospital Oakland, Oakland
- Rady Children's Hospital, San Diego
被験者募集中第2相
22歳以下 · 全性別 · 2026/09/04更新 · NCT02559778Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- UCSF Benioff Children's Hospital Oakland, Oakland
- Rady Children's Hospital, San Diego
被験者募集中第1/2相
30歳以下 · 全性別 · 2026/09/03更新 · NCT06541262Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Kaiser Permanente Downey Medical Center, Downey
- Loma Linda University Medical Center, Loma Linda
- Children's Hospital Los Angeles, Los Angeles
- 他9件
被験者募集中第3相
365 Days – 30 Years · 全性別 · 2026/08/25更新 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Children's Hospital Los Angeles, Los Angeles
- Children's Hospital of Orange County, Orange
- UCSF Medical Center-Mission Bay, San Francisco
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
- UCSF Benioff Children's Hospital Oakland, Oakland
- Rady Children's Hospital, San Diego
被験者募集中第2相
12 Months – 21 Years · 全性別 · 2026/08/12更新 · NCT05489887SPEARHEAD-3 Pediatric Study
- Stanford University, Palo Alto
被験者募集中第1/2相
2歳〜21歳 · 全性別 · 2026/08/11更新 · NCT05642455PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Cedars-Sinai Medical Center, Los Angeles
- University of California, San Francisco, San Francisco
被験者募集中第1/2相
1歳〜30歳 · 全性別 · 2026/07/22更新 · NCT06721689NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Children's Hospital Los Angeles, Los Angeles
- UCSF Benioff Children's Hospital, San Francisco
被験者募集中第2相
1歳〜31歳 · 全性別 · 2026/07/20更新 · NCT06450041Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
- Lucille Packard Children's Hospital Stanford, Palo Alto
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/05/19更新 · NCT04901702Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
- Stanford University, Palo Alto
被験者募集中第1相
2歳〜30歳 · 全性別 · 2026/05/07更新 · NCT06500819Neuroblastoma Biology Study
- Children's Hospital Los Angeles, Los Angeles
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
被験者募集中観察研究
31 Days – 99 Years · 全性別 · 2026/03/23更新 · NCT01587300ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。